RGS RGS Healthcare Solutions

See where your brand is bought, priced and challenged

Hospital tenders publish what buyers pay for branded medicines and when competitors arrive. RGS turns that into a market access view: who buys your brand, at what price, when generics or biosimilars will tender against it, and how prices have moved in comparable cases.

What makes tendering hard for branded pharma

01

Loss of exclusivity arrives tender by tender

Generic and biosimilar entry reaches markets at different times. It follows each buyer's tender calendar, and the first rounds set the price for the rest.

02

Price references travel

A low award in one market becomes the benchmark for the next. Sequencing matters as much as the price itself.

03

Hospital demand is opaque

Volumes and prices in hospital channels are rarely visible in sales data, but they are often published in tenders.

How RGS helps

Discovery, award intelligence and pricing guidance on one data layer, with our team available when you need analysis or hands-on support.

Used by market access managers, brand and franchise leads, heads of hospital business, pricing managers, business development.

  • A map of the buyers tendering your molecule, with current holders and expiry dates
  • Price erosion curves from comparable loss of exclusivity cases
  • Early warning when competitor products start winning lots
  • Market-by-market price references for launch and access planning
  • Bespoke analysis from our consulting team when a decision needs it

Using tender data for market access as well as bidding

Branded pharmaceutical and medtech companies wanted to know where their products would be bought, at what price and against whom.

Beyond generics
Tender data is published for branded medicines and devices too, which allowed a full view of buyers, prices and competitors.
Market selection
For a medical device manufacturer we ranked markets by demand, price level and competitive intensity.
Go-to-market support
We identified the right distribution partners and the tenders to target first.

Ranked

Target markets by tender demand and price

Shortlist

Of partners for each priority market

All case studies

Also for: Generics and biosimilars, MedTech, Partner-led manufacturers

Questions teams ask us

When will generics or biosimilars tender against our brand?

Entry follows each buyer's tender calendar, so the timing differs by buyer. RGS shows who buys your molecule, when each contract ends and which competitors already hold or are filing for an authorisation.

How fast do hospital prices fall after loss of exclusivity?

It differs widely by market and buyer. RGS shows the price path in comparable cases, lot by lot, which lets you plan the sequence of markets from comparable cases.

More questions? See all questions, how pricing works, the platform and integrations or who is behind RGS.

See what the tender data says about your portfolio

We load your products and markets before the session, so the conversation starts with your own tenders.